Formulations of enzalutamide

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11839689
APP PUB NO 20230210778A1
SERIAL NO

17985235

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ASTELLAS PHARMA INC.; MEDIVATION PROSTATE THERAPEUTICS LLC

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Everett, Jason A Bend, US 13 38
Irie, Ryousuke Tokyo, JP 11 19
Kanbayashi, Atsushi Tokyo, JP 12 22
Konagurthu, Sanjay Bend, US 18 30
Lorenz, Douglas Alan Bend, US 21 72
Matz, Sheila North Conway, US 11 19
Nishimura, Koji Tokyo, JP 77 399
Oba, Shinsuke Tokyo, JP 15 25
Sakai, Toshiro Tokyo, JP 27 46
Takaishi, Yuuki Tokyo, JP 29 237
Toyota, Hiroyasu Tokyo, JP 13 21
Wald, Randy J Bend, US 16 125

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 12, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 12, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 12, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00